Acknowledgments
The authors would like to thank all the staff who assisted with analysing the samples at the four laboratories.
Author contributions: SH and JO designed the study and analysed the data. SH, JO, AB and SB were involved in sample analysis and data transfer. SH wrote the first draft of the manuscript. All authors edited, reviewed and approved the final manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Piketty M-L, Polak M, Flechtner I, Gonzales-Briceno L, Souberbielle J-C. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med 2017;55:780–8.10.1515/cclm-2016-0606Search in Google Scholar PubMed
2. Jenkins Colon P, Greene D. Biotin interference in clinical immunoassays. J Appl Lab Med 2018;2:952–9.10.1373/jalm.2017.024257Search in Google Scholar PubMed
3. Giovanella L, Imperiali M, Kasapic D, Ceriani L, Trimboli P. Euthyroid Graves’ disease with spurious hyperthyroidism: a diagnostic challenge. Clin Chem Lab Med 2019;57:e94–6.10.1515/cclm-2018-0759Search in Google Scholar PubMed
4. Katzman B, Lueke A, Donato L, Jaffe A, Baumann N. Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clin Biochem 2018;60:11–6.10.1016/j.clinbiochem.2018.07.004Search in Google Scholar PubMed
5. Grimsey P, Frey N, Bendig G, Zitzler J, Lorenz O, Kasapic D, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinet 2017;2:247–56.10.4155/ipk-2017-0013Search in Google Scholar
6. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Metab Toxicol 2016;12:327–44.10.1517/17425255.2016.1136288Search in Google Scholar PubMed
7. Trambas C, Lu Z, Yen T, Sikaris K. Characterisation of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Ann Clin Biochem 2018;55:205–15.10.1177/0004563217701777Search in Google Scholar PubMed
8. Piketty M, Prie D, Sedel F, Bernard D, Hercend C, Chanson P, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med 2017;55:817–25.10.1515/cclm-2016-1183Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
